MiR-625 overexpression suppresses glioma growth in vivo. (A) Tumor growth curves after subcutaneous injection of nude mice with U87 cells stably expressing miR-NC or miR-625 (n = 4). Tumor volumes were measured every 3 d from days 3 to 30. (B-F) Analysis of miR-NC- and miR-625-expressing U87 tumors on day 30 after injection: representative tumor images (B); tumor weights (C); immunohistochemical staining of AKT2, Ki-67, and cleaved caspase 3 (D); immunofluorescent staining of AKT2 protein (E); and western blot analysis of AKT2, with GAPDH as the loading control (F). *P < 0.01, **P < 0.01, ***P < 0.001.